Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5627083 | Clinical Neurology and Neurosurgery | 2016 | 6 Pages |
Abstract
MGMT promoter methylation and IDH1 mutation were associated with PsPD and predicted a longer median survival in GBM patients after TMZ-based chemoradiotherapy. Genetic analyses of the MGMT promoter and IDH1 may allow us to effectively treat GBM patients.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Hailong M.D., Jiye M.D., Gang M.D., Jianning M.D., Xuezhen M.D.,